Protein having hemolytic activity and gene encoding the protein
View Patent ↗Novel proteins having hemolytic activity giving the new approach of development of the drugs, and having the following property are provided: (1) having hemolytic activity; (2) having a molecular weight of about 50,000 Da (determined by SDS gel electrophoresis); and (3) having an amino acid sequence represented by any of SEQ ID NO 1 and SEQ ID NO 2 as a partial amino acid sequence represented by the following amino acid sequences (1) and (2); Amino acid sequence (1): Tyr-Arg-Asp-Gln-Glu-Leu-Glu-Asp-Asn-Val-Lys Amino acid sequence (2): Lys-Trp-Pro-Asp-Tyr-Phe-Val-Tyr-Met-Glu-Ser-Ser-Ala-His-Gly-Tyr-Ile-Arg (wherein, an amino acid residue is written by the 3 letters notation defined by IUPAC and IUB) obtained from nematocyst of Carybdea alata.
1. An isolated hemolytic protein, comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, wherein the hemolytic protein has a molecular weight of about 50,000 Da.
2. The hemolytic protein according to claim 1 , wherein the protein is obtained from a nematocyst of Carybdea alata.
3. An isolated hemolytic protein, comprising a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO:2, wherein the protein is obtained from a cultivated product of a transformed cell prepared by genetic recombination.
4. An isolated hemolytic protein comprising the sequence of SEQ ID NO: 3.
5. The hemolytic protein according to claim 3 , wherein the protein is obtained from the cultivated solution of a transformed cell prepared by genetic recombination using a polynucleotide which hybridizes with a polynucleotide encoding at least one amino acid sequence selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 2.
6. A process for preparing the hemolytic protein of claim 1 , comprising ultrasonicating at least one nematocyst of Carybdea alata in phosphoric acid buffer solution; centrifuging the mixture; extracting the supernatant fluid after centrifugation; and extracting the hemolytic protein from said supernatant by ion exchange high performance liquid chromatography or gel filtration high performance liquid chromatography.
7. The process for preparing the hemolytic protein of claim 6 , wherein the phosphoric acid buffer solution is 10 mM phosphoric acid buffer solution of pH 6.0 containing at least 0.1 M NaCl at or below 10° C.
8. A pharmaceutical composition comprising the hemolytic protein according to claim 3 .
9. The pharmaceutical composition to claim 8 , wherein the composition has a platelet agglutination effect.